Kiniksa CEO Patel's trust sells 151,300 shares

Q: How many KNSA shares did The Anglia 2013 Revocable Trust sell?

The Anglia 2013 Revocable Trust sold 151,300 Class A ordinary shares on November 4, 2026, in five reported tranches. Their weighted-average sale prices ranged from $92.35 to $96.05 per share. The transactions were effected pursuant to a 10b5-1 plan Sanj K. Patel executed on July 30, 2026.

Q: What option exercise did KNSA Chairman & CEO Sanj K. Patel report?

Sanj K. Patel reported exercising options for 145,763 Class A ordinary shares at $17.92 per share on November 4, 2026. The acquired shares were held by The Anglia 2013 Revocable Trust, and the transaction was effected pursuant to a 10b5-1 plan executed on July 30, 2026.

The trust's five sale tranches carried weighted-average prices from $92.35 to $96.05 per share under a plan adopted July 30, 2026.

Available on EDGAR 11/06/2026 - 04:52 PM EST Accepted by SEC EDGAR 11/06/2026 - 04:52 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Very Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc Chairman & CEO Sanj K. Patel reported exercising options for 145,763 Class A ordinary shares at $17.92 per share on November 4, 2026; the acquired shares were held by The Anglia 2013 Revocable Trust. The trust also sold 151,300 Class A ordinary shares that day in five tranches, at weighted-average prices from $92.35 to $96.05 per share. The transactions were effected pursuant to a 10b5-1 plan Patel executed on July 30, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Patel Sanj K

Role CHAIRMAN & CEO

Sold 151,300 shs ($14.33M)

Approx. gross sale proceeds $14.33M

Approx. exercise cost $2.61M

Type	Security	Shares	Price	Value
Exercise	Share Option ^{F1, F7}	145,763	$0.00	$0.00
Exercise	Class A Ordinary Share ^F1	145,763	$17.92	$2.61M
Sale	Class A Ordinary Share ^{F1, F2}	1,460	$92.35	$135K
Sale	Class A Ordinary Share ^{F1, F3}	11,335	$93.54	$1.06M
Sale	Class A Ordinary Share ^{F1, F4}	81,742	$94.20	$7.70M
Sale	Class A Ordinary Share ^{F1, F5}	29,845	$95.48	$2.85M
Sale	Class A Ordinary Share ^{F1, F6}	26,918	$96.05	$2.59M
Holding	Class A Ordinary Share	--	--	--
Holding	Class A Ordinary Share	--	--	--

Holdings After Transaction: Share Option — 0 contracts (Direct); Class A Ordinary Share — 774,500 shares (Indirect, Held by The Anglia 2013 Revocable Trust); Class A Ordinary Share — 92,348 shares (Indirect, Held by The Patel Family Irrevocable Trust of 2025); Class A Ordinary Share — 109,795 shares (Indirect, Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016)

Footnotes (7)

F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.
F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.945 and $92.655. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.95 and $93.92. The price 5reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.95 and $94.94. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F5. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.95 and $95.94. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F6. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.95 and $96.19. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F7. The option is fully vested and exercisable.

Key Figures

Shares acquired through option exercise: 145,763 shares Option exercise price: $17.92 per share Shares sold: 151,300 shares +5 more

8 metrics

Shares acquired through option exercise 145,763 shares November 4, 2026; held by The Anglia 2013 Revocable Trust

Option exercise price $17.92 per share November 4, 2026

Shares sold 151,300 shares The Anglia 2013 Revocable Trust; November 4, 2026

Sale tranche 1,460 shares at a weighted-average sale price of $92.35 per share November 4, 2026

Sale tranche 11,335 shares at a weighted-average sale price of $93.54 per share November 4, 2026

Sale tranche 81,742 shares at a weighted-average sale price of $94.20 per share November 4, 2026

Sale tranche 29,845 shares at a weighted-average sale price of $95.48 per share November 4, 2026

Sale tranche 26,918 shares at a weighted-average sale price of $96.05 per share November 4, 2026

Key Terms

10b5-1 plan, weighted average sales price, fully vested and exercisable

3 terms

10b5-1 plan regulatory

"pursuant to a 10b5-1 plan executed by the reporting person"

A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.

weighted average sales price financial

"reflects a weighted average sales price"

fully vested and exercisable financial

"The option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KNSA shares did The Anglia 2013 Revocable Trust sell?

The Anglia 2013 Revocable Trust sold 151,300 Class A ordinary shares on November 4, 2026, in five reported tranches. Their weighted-average sale prices ranged from $92.35 to $96.05 per share. The transactions were effected pursuant to a 10b5-1 plan Sanj K. Patel executed on July 30, 2026.

What option exercise did KNSA Chairman & CEO Sanj K. Patel report?

Sanj K. Patel reported exercising options for 145,763 Class A ordinary shares at $17.92 per share on November 4, 2026. The acquired shares were held by The Anglia 2013 Revocable Trust, and the transaction was effected pursuant to a 10b5-1 plan executed on July 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sanj K

(Last)

(First)

(Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON

W1J 7NJ

(City)

(State)

(Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHAIRMAN & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Ordinary Share	11/04/2026		M⁽¹⁾		145,763	A	$17.92	925,800	I	Held by The Anglia 2013 Revocable Trust
Class A Ordinary Share	11/04/2026		S⁽¹⁾		1,460	D	$92.35⁽²⁾	924,340	I	Held by The Anglia 2013 Revocable Trust
Class A Ordinary Share	11/04/2026		S⁽¹⁾		11,335	D	$93.54⁽³⁾	913,005	I	Held by The Anglia 2013 Revocable Trust
Class A Ordinary Share	11/04/2026		S⁽¹⁾		81,742	D	$94.2⁽⁴⁾	831,263	I	Held by The Anglia 2013 Revocable Trust
Class A Ordinary Share	11/04/2026		S⁽¹⁾		29,845	D	$95.48⁽⁵⁾	801,418	I	Held by The Anglia 2013 Revocable Trust
Class A Ordinary Share	11/04/2026		S⁽¹⁾		26,918	D	$96.05⁽⁶⁾	774,500	I	Held by The Anglia 2013 Revocable Trust
Class A Ordinary Share								92,348	I	Held by The Patel Family Irrevocable Trust of 2025
Class A Ordinary Share								109,795	I	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option	$17.92	11/04/2026		M⁽¹⁾			145,763	⁽⁷⁾	03/03/2029	Class A Ordinary Share	145,763	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.945 and $92.655. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.95 and $93.92. The price 5reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.95 and $94.94. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

5. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.95 and $95.94. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

6. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.95 and $96.19. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

7. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR